Mark D Flanagan

US Patent:

6965027, Nov 15, 2005

Filed:

Dec 4, 2002

Appl. No.:

10/310078

Inventors:

Mark E. Flanagan - Gales Ferry CT, US
Zheng J. Li - Quaker Hill CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D401/12

US Classification:

544280

Abstract:

This invention relates to novel amorphous and crystallline forms of 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile mono citrate salt, useful as inhibitors of protein kinases, and to their methods of preparation.

US Patent:

7301023, Nov 27, 2007

Filed:

May 23, 2002

Appl. No.:

10/154699

Inventors:

Mark E. Flanagan - Gales Ferry CT, US
Michael J. Munchhof - Salem CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 487/04
C07D 213/74
A61K 31/519
A61P 35/00
C07B 57/00

US Classification:

544280, 546 22, 546223

Abstract:

A method for resolving enantiomers of a compound containing the structure of the forula: wherein Ror Rmay contan one or more asymmetric centers, by mixing a racemic mixture of enantiomers of a compound, containing the structure of said formula; in a solvent, with a resolving compound having a defined sterospecificity, to form a solution and with said resolving agent being capable of binding with at least one but not all of said enantiomers to form a precipitate, containing said at least one of said enantiomers in sterospecific form and collecting either the precipitate and purifying it or collecting the solution with contained other of said enantiomers and recrystallizing the enantiomer contained in said solution.

US Patent:

7432370, Oct 7, 2008

Filed:

Jun 15, 2004

Appl. No.:

10/869101

Inventors:

Glenn E. Wilcox - Cranston RI, US
Mark E. Flanagan - Gales Ferry CT, US
Michael J. Munchhof - Salem CT, US
Ton Vries - Groningen, NL
Christian Koecher - St. Ursan, CH

Assignee:

Pfizer Inc. - Groton CT

International Classification:

C07D 487/04
C07D 213/74
A61K 31/519
A61P 35/00
C07B 57/00

US Classification:

540280

Abstract:

The present application discloses compounds of the formula.

US Patent:

7803805, Sep 28, 2010

Filed:

Jan 10, 2005

Appl. No.:

11/032990

Inventors:

Mark E. Flanagan - Gales Ferry CT, US
Zheng J. Li - Quaker Hill CT, US

Assignee:

Pfizer Inc. - Madison NJ

International Classification:

A61P 37/06
A61P 11/06
C07D 487/04
A61K 31/519

US Classification:

5142651, 544280

Abstract:

This invention relates to novel amorphous and crystallline forms of 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3 -oxo-propionitrile mono citrate salt, useful as inhibitors of protein kinases, and to their methods of preparation.

US Patent:

8252782, Aug 28, 2012

Filed:

Dec 18, 2009

Appl. No.:

12/641343

Inventors:

Steven Joseph Brickner - Ledyard CT, US
Mark Edward Flanagan - Gales Ferry CT, US
Manjinder Singh Lall - East Lyme CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 417/14
A61K 31/4439
A61P 31/04
C07D 413/04
C07D 401/04
C07D 213/81
C07D 417/12

US Classification:

51421002, 540353, 5462694, 5462724, 546296, 548128, 548196, 549417

Abstract:

The invention relates to compounds of formula (I):.

US Patent:

8324198, Dec 4, 2012

Filed:

Jul 26, 2012

Appl. No.:

13/558989

Inventors:

Steven Joseph Brickner - Ledyard CT, US
Mark Edward Flanagan - Gales Ferry CT, US
Manjinder Singh Lall - East Lyme CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 417/14
A61K 31/4439
A61P 31/04
C07D 413/04
C07D 401/04
C07D 213/81
C07D 417/12

US Classification:

51421002, 540363

Abstract:

The invention relates to compounds of formula (I):.

US Patent:

20080293646, Nov 27, 2008

Filed:

Mar 12, 2008

Appl. No.:

12/047154

Inventors:

Thomas V. Magee - Mystic CT, US
Usa Reilly - West Haven CT, US
Mark Carl Noe - Mystic CT, US
Mark E. Flanagan - Gales Ferry CT, US
Zhengong Bryan Li - East Lyme CT, US
Richard Allen Buzon - Stonington CT, US
Daniel William Widlicka - Gales Ferry CT, US

International Classification:

A61K 31/7048
C07H 17/08
C07D 471/02
A61P 31/04

US Classification:

514 29, 536 74, 546122

Abstract:

The invention relates to compounds of Formula (I):wherein R, Rand X are as defined herein. The invention also relates to pharmaceutical compositions and methods of treating bacterial infections using compounds of Formula (I).

US Patent:

20220387402, Dec 8, 2022

Filed:

May 15, 2020

Appl. No.:

17/612672

Inventors:

- New York NY, US
Scott W. Bagley - Mystic CT, US
John M. Curto - Mystic CT, US
Matthew Dowling - Old Lyme CT, US
David James Edmonds - Riehen, CH
Dilinie Fernando - Jamaica Plain MA, US
Mark E. Flanagan - Gales Ferry CT, US
Kentaro Futatsugi - Sharon MA, US
David Andrew Griffith - Sudbury MA, US
Kim Huard - Berkeley CA, US
Gajendra Ingle - New Haven CT, US
Wenhua Jiao - Salem CT, US
Shawn M. LaCasse - Griswold CT, US
Yajing Lian - Waterford CT, US
Chris Limberakis - Pawcatuck CT, US
Allyn T. Londregan - Barrington RI, US
Alan M. Mathiowetz - Waltham MA, US
David Walter Piotrowski - Waterford CT, US
Roger B. Ruggeri - Waterford CT, US
Kristin Wiglesworth - Germantown MD, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 31/438
A61K 31/496
A61K 31/4545
A61K 31/454
A61K 31/5377
A61K 31/506
A61K 31/46
A61K 45/06
A61K 38/26
A61K 38/28
A61K 38/17
A61P 1/16

Abstract:

In part, the invention provides a new combination comprising (1) a GLP-1R agonist and (2) an ACC inhibitor or a DGAT2 inhibitor, or a KHK inhibitor or FXR agonist. The invention further provides new methods for treating diseases and disorders, for example, fatty liver, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, nonalcoholic steatohepatitis with liver fibrosis, nonalcoholic steatohepotitis with cirrhosis, and nonalcoholic steatohepatitis with cirrhosis and with hepatocellular carcinoma or with a metabolic-related disease, obesity, and type 2 diabetes, for example, using the new combination described herein.